NemaGen Discoveries is an early-stage Rutgers University spinout company founded in 2019 by an expert in parasitology and immunology, Marc Siracusa. NemaGen aims to develop novel therapies for chronic inflammation and mast cell-related diseases. They investigated how the body naturally controls mast cell development during parasitic nematode infections, which allowed the identification of therapeutic targets for eliminating and preventing excessive inflammation. Thus, they aim to develop therapies that modulate the Mast cell development or function to mitigate inflammatory diseases. The main advantage of NemaGen’s approach is that it has the potential to be preventative, rather than just providing symptom management.

NemaGen Discoveries

We look forward to seeing you all at Day 3 of BIO!

We are thrilled to announce that we will be awarded a $50,000 New Jersey SBIR Support Program Grant from the New Jersey Commission on Science, Innovation and Technology! 

We very much appreciate all the support from the NJ-EDA and could not think of a better place to be centered than New Jersey!

We have been very quiet on social media lately, but as we are gearing up for BIO this week, we wanted to give a recap on what we have been up to over the past year!

1) Carbonic anhydrase 1 (Car1) program advancements: We have made a ton of progress on our Car1 program over the past year. In short, Car1 is highly expressed by mast cell precursor cells. We are developing novel small molecule inhibitors to Car1 that impair mast cell development. Our goal is to safely reduce mast cell numbers for people with severe allergic disorders, including systemic mastocytosis, food allergy, and asthma. Over the past year, we have advanced a lead Car1 inhibitor that is orally available, potently impairs mastocytosis development in mice, and does not induce toxicity in rats.

2) Initiation of our carbonic anhydrase 4 (Car4) therapeutic program: Last July, we initiated a second carbonic anhydrase-targeted program, for Car4. Car4 is highly downregulated proteins in the lungs of patients with COPD-emphysema and idiopathic pulmonary fibrosis (IPF). We have identified that Car4 treatment protects mice from emphysema onset and improves survival following pulmonary fibrosis induction in established murine models of emphysema and pulmonary fibrosis, respectively. Importantly, we have identified novel mechanisms of action for why Car4 is protective in these diseases. We are thrilled to have licensed this technology from Rutgers and to have advanced this technology over the past year so that we can help provide emphysema and IPF patients with a critically needed novel therapy!

3) NJ-DOL Innovation and Research Fellowship Program (IRFP) postdoc award: In January, we were awarded with an IRFP grant from the NJ-DOL that provides funding for a NJ startup to bring on a postdoctoral fellow. With that award, we were elated to bring on John Ponessa to our team! Dr. Ponessa is an expert in carbonic anhydrase research whereupon his thesis focused on the role of Car4 in pulmonary disease. Dr. Ponessa is helping us to advance both our Car1 and Car4 therapeutic programs over the next year! 

4) Dr. Adrian Piliponsky joins our Scientific Advisory Board (SAB): We are thrilled to announce that Dr. Adrian Piliponsky joined our SAB in January of this year! Dr. Piliponsky is a renowned expert in mast cell biology and models of mast cell disease. 

5) Funding from the New Jersey Economic Development Authority (NJ-EDA) Commission on Science, Innovation, and Technology (CSIT): Last but not least, we received two grants from the NJ-EDA CSIT earlier this year, including a $25,000 SBIR direct funding award and a $40,000 Catalyst Research and Development (R&D) Voucher. We are ecstatic to receive these awards, as they will allow us to substantially advance our therapeutic programs!

We have been up to much more, but this post is already way too long. We look forward to meeting with all of you that are traveling to San Diego for BIO next week!

NemaGen is thrilled to announce that we were granted an Innovation and Research Fellowship Program (IRFP) award from the New Jersey Department of Labor and Workforce Development (NJ-DOL). This award provides salary support for a NemaGen postdoc to help advance our drug development programs. We would like to thank the NJ-DOL for tremendous support! #NJDOL

Living with mast cell diseases means navigating unpredictable symptoms and making tough adjustments daily. These stories highlight the resilience required, from missed moments to careful planning. Today, we stand together, sharing experiences to foster understanding and work toward a future where living with mast cell diseases is met with greater support and awareness. Together, we advocate for a world where no one feels alone in their journey.

NemaGen's President (Mark Siracusa) and CEO (Nick Shubin) will be attending and presenting at the BIONJ-partnering conference at the Liberty Science Center, May 13th, 2025. 

Additionally, we will also be attending the 2025 BIO International conference in Boston, June 16th-19th, 2025. 

We have lots of exciting updates and are currently setting meetings with potential investors and partners. If you plan on attending, please reach out to us for a meeting via the partnering portals, email, or linked in! #bio #bionj

It has been a pleasure to be embraced by the innovative and highly collaborative environment of NJ. It has been amazing to witness all the exciting therapeutic and technological advancements! 

Our founder, Mark Siracusa, did a tremendous job pitching today in a packed room at the BIO-NJ partnering conference! Thanks to all who attended to learn about our novel mast cell targeting therapeutic program!

NemaGen Discoveries

Business:

Drug notes:

About: